FDA Clears Xenix Medical's Lux Spinal Fusion System

Xenix Medical has announced that its Lux expandable lumbar interbody fusion system has received clearance from the US Food and Drug Administration (FDA). This clearance allows for the product's launch into the US market, expanding Xenix's portfolio.

The Lux system is distinguished by its NeoWave matrix spacer implants, engineered to replicate natural bone structure and minimize the risk of implant subsidence. It also features NanoActiv technology, a surfacing technology designed to ensure implants remain securely in place.

Developed in response to market demand for expandable interbody fusion devices that do not compromise fusion potential, Lux offers enhanced flexibility for surgeons. It is specifically designed for posterior lumbar interbody fusion (PLIF) and transforaminal lumbar interbody fusion (TLIF) surgeries, allowing for post-implantation expansion.

These procedures are common for stabilizing lumbar vertebrae, addressing issues like nerve compression, degenerative disc disease, or spinal stenosis. The global spinal fusion market is experiencing growth, projected to reach approximately $17.5 billion by 2035.

Xenix Medical founder Robert Hirschl noted that expandable cages have historically faced challenges with fusion rates and subsidence. Lux aims to address these shortcomings through its design, which includes a large graft window and advanced surface and endplate technologies. Early results have been very encouraging.

This FDA clearance for Lux follows closely on the heels of the agency's approval of Xenix's Riva posterior fixation system just last week. The Riva system is a set of pedicle screws used for stabilizing spinal segments in various thoracic, lumbar, and sacral spine surgeries.